Endocrinology

Your daily dose of the clinical news you may have missed.

The Advisory Panel laid out 4 priority actions for clinicians, policy makers, and industry.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Jonathan Bonnet, MD, MPH, discusses common side effects of GLP-1 medications for obesity and how nutritional and behavioral strategies can help mitigate them.

Coauthor of a recent joint advisory, Jonathan Bonnet, MD, MPH, explains how it emerged in response to the growing use of GLP-1 medications for obesity treatment.

Obesity medicine specialist Monu Khanna, MD, discusses the critical role of primary care in obesity-related risk reduction through lifestyle, behavior, and emerging therapies.

Both metformin and GLP-1 RAs have been studies for their neuroprotective effects; this study is the first head-to-head investigation and supports further research.

Individuals on GLP-1 therapy express significant concern about muscle loss, prompting lifestyle changes and highlighting the need for informed primary care guidance.

Monu Khanna, MD, offers 3 takeaways for primary care: address obesity as root cause, reduce stigma, and explore new treatments to reduce cardiovascular risk.

Type 2 diabetes and its high and rising rates in the US are the result of a perfect storm of converging systemic, behavioral, environmental, and economic factors.

Dr Khanna discusses how PCPs can use patient relationships to tailor lifestyle advice and manage obesity-related cardiometabolic disease.

Dr Khanna urges early screening for cardiometabolic risk in patients with obesity and highlights the role of primary care in prevention and education.

Without a shift in the approach to disease prevention and management in the US, the health system won't be able to handle the burden of our morbidity, says Richard Rosenfeld, MD, MPH, MBA.

ENDO 2025. People with inconsistent access to GLP-1 medications still achieved clinically significant weight loss when therapy was combined with lifestyle changes and coaching.

ENDO 2025: The publications reflect growing consensus that integration of endocrine screening into standard clinical workflows is essential for early risk detection and long-term disease prevention.

Individuals newly classified with obesity using the European framework were found to be overall sicker and at greater risk for mortality.

Richard Rosenfeld, MD, MPH, MBA, led the development of lifestyle medicine guidelines to treat or even reverse prediabetes and type 2 diabetes.

A new analysis of the CAHtalog phase 3 study showed approximately 95% of participants experienced either high glucocorticoid exposure or elevated androstenedione levels during treatment.

Monu Khanna, MD, discusses the benefits of behavioral strategies, including yoga, breathwork, and dancing, in reducing cardiovascular disease risk in patients with obesity.

Lead author for the American College of Lifestyle Medicine's new clinical practice guideline discusses the broad endorsement for the recommendations across participating groups.

ENDO 2025. Older adults, rural populations, and residents in the Midwest experienced the highest mortality rates, according to new data.

Treatment should address root causes, including lifestyle modifications, stress management, and gut health, Monu Khanna, MD, told Patient Care.

Key predictors of the severity of self-reported cognitive complaints among nurses going through menopause included symptom severity and climacteric stage.

Lifestyle medicine integrates a spectrum of therapeutic lifestyle interventions best delivered by specialists who are often available to create a "virtual" team.

Dr Khanna breaks down the bidirectional relationship and explains why standard pain management often falls short for people with obesity.

A recent study highlights the importance of medication adherence for significant weight loss and improved glycemic control in obesity treatment with GLP-1 agonists.

Richard Rosenfeld, MD, MPH, MBA, lead author of new guidelines on sustained lifestyle change as central to treating, even reversing T2D, answers the question.

Monu Khanna, MD, discusses common medications, non-drug strategies, and holistic approaches to improve outcomes.